D. Boral Capital upgraded Artelo Biosciences, Inc. ARTL on Tuesday.The analyst upgraded from Hold to Buy and introduced a price forecast of $20.Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced peripheral neuropathy (CIN) with the lead program.”ART27.13 is a Phase 2 asset, a selective benzimadazole agonist acquired from AstraZeneca Plc AZN.The analyst wrote that ART27.13 showed potential to stimulate appetite and promot ...

7月8日，由深圳市人力资源和社会保障局、华为技术有限公司与深圳人才集团有限公司合作共建的全球 数智人才发展创新基地在深启动建设。这也是华为公司本部首次深度参与建设的全球人才培养标杆项 目。 据悉，该基地由深圳人才集团旗下全资子公司"深圳数智国际人才发展有限公司"负责运营，分两期建 设，一期选址罗湖区深业泰富科创大厦，年计划培训规模1.5万人，二期将拓展至4万人，5年内预计培 养高质量数智人才超20万人，致力于填补国内ICT（信息与通信技术）根技术人才系统性培养领域空 白。基地计划2026年成为国家级产教融合示范基地，2027年成为国家级高技能人才培训基地，2030年成 为全球数智人才培养高地。 在全球数字化进程加速背景下，信息与通信技术成为经济社会发展的核心驱动力，ICT人才短缺问题凸 显。根据《中国ICT人才生态白皮书》显示，全国范围内ICT认证人才缺口达2000万人。为解决人才供 给瓶颈，深圳市人力资源保障局、华为技术有限公司、深圳市人才集团有限公司三方签署合作协议，政 府、行业龙头企业、国资运营平台将深入联动，整合政策制定、技术牵引、人才培养、资源统筹、运营 服务等优势资源，共同培育数智人才培养生态，创 ...

ZyVersa Therapeutics, Inc. ZVSA stock was trading higher on Tuesday, with a session volume of 160.9 million compared to the average volume of 4.03 million as per data from Benzinga Pro.What HappenedZyVersa Therapeutics provided regulatory and product support for FDA-authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a patient with ApoCII amyloidosis.Emergency Compassionate Use, also known as Emergency Expanded Access, is a pathway that allows patients with severe or immediately ...

Mark Zuckerberg’s Meta has reportedly forked over “tens of millions of dollars” to poach one of Apple’s top artificial intelligence researchers as the tech giant continued to add to a murderers’ row of high-paid talent.Ruoming Pang, who led the team responsible for developing Apple’s AI models, will become the latest member to join Meta’s new “Superintelligence Lab,” Bloomberg reported, citing sources with knowledge of the matter.Meta reportedly lured Pang, who had worked at Apple since 2021, with a compens ...

Key Takeaways BILL's Q3 fee-based revenues rose 17% to $252.1M, driven by an 11% gain in TPV to $79.4B. Growth in Instant Payments and Supplier Payments Plus fueled higher monetization and platform use. Despite gains, BILL saw softer spending and a sequential TPV dip as larger rivals tightened competition.BILL Holdings (BILL) continues to gain momentum as transaction fee revenues increased 17% year over year to $252.1 million in the third quarter of fiscal 2025. This growth was largely driven by an 11% in ...

Shares in biotech company Recursion Pharmaceuticals (RXRX 11.46%) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.Taking full ownership of an important drugThe de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (RLYB 39.57%). REV102 is being developed to treat hypophosphatasia (HPP) -- a rare and debilitating genetic disorder that affects bone development.Acc ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.The Dow traded down 0.35% to 44,249.09 while the NASDAQ gained 0.07% to 20,427.63. The S&P 500 also fell, dropping, 0.03% to 6,228.39.Check This Out: Top 2 Industrials Stocks You May Want To Dump This QuarterLeading and Lagging SectorsEnergy shares jumped by 2.1% on Tuesday.In trading on Tuesday, utilities stocks dipped by 1.9%.Top HeadlineThe US Manheim Used Vehicle Value Index increased 1.6% m ...

AST SpaceMobile (ASTS 0.85%) stock recorded huge gains across June's trading. The space technology company's share price surged 102.6% in a month that saw the S&P 500 (^GSPC -0.04%) rise 5% and the Nasdaq Composite (^IXIC 0.06%) jump 6.6%.Excitement surrounding defense technology plays and bullish momentum for the broader market helped AST stock close out the period with huge gains. New partnership announcements, investment speculation, and analyst coverage also helped power the rally. AST SpaceMobile stock ...

Pacific Biosciences of California (PACB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Esti ...

Maintain BUY. We are positive on the global potential of Innovent's rich innovative pipelines. Innovent is on track to achieve EBITDA breakeven this year. Backed by smooth development of IBI363, we improved our possibility of success for the asset and raised our DCF-based TP to HK$102.95 from HK$94.74. 机构：招银国际 研究员：Jill WU/Andy WANG IBI363 positioned as a promising next-generation IO therapy with Ph3 trials underway. Strong survival benefits and broad potential position IBI363 (PD-1/IL-2) as a potential bloc ...